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Abstract
Here we report that an engineered microbial cytochrome P450 BM-3 (CYP102A1 subfamily)
efficiently catalyzes the α-hydroxylation of phenylacetic acid esters. This P450 BM-3 variant also
produces the authentic human metabolite of buspirone, R-6-hydroxybuspirone, with 99.5% ee.
Biocatalytic processes are becoming increasingly important in organic synthesis1 due to their
unique selectivity advantages over conventional methods.2, 3 Common biocatalytic
transformations include enantioselective transesterification,4 reduction of ketones,2 Baeyer-
Villiger oxidation5 and epoxide opening.6 Recently, biocatalytic hydroxylations have attracted
considerable interest.7,8 Here we report a variant of cytochrome P450 BM-3 (BM-3; isolated
from Bacillus megaterium) capable of efficient and highly enantioselective hydroxylation at
the alpha position of certain carboxylic and peptide groups.
BM-3 is a well-studied, NADPH-dependent monooxygenase that hydroxylates long-chain
fatty acids at the ω-1, ω-2, and ω-3 positions at high rates.9 BM-3 has provided an evolvable
protein framework for obtaining modified or new activities. Rational design and directed
evolution approaches have created BM-3 variants with activity on medium-chain fatty acids,
10 high selectivity for 2-hydroxylation of n-alkanes such as hexane,11 activity on aromatic
compounds12 and the ability to oxidize ethane to ethanol.13 BM-3 variants were also recently
shown to yield human drug metabolites.14
2-Aryl-2-hydroxyacetic acid derivatives are pharmaceutical building blocks for semi-synthetic
penicillins, cephalosporin and antiobesity agents.15 Mandelic acid derivatives have been found
to act as thrombin inhibitors and anticoagulants.16 Due to the high level of interest in these
compounds, a number of methods have been developed for their synthesis in enantiomerically
pure form.17 These methods often use racemic substrates or intermediates for resolution or
selective hydrolysis rather than direct enantioselective hydroxylation at the targeted position.
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No cytochrome P450 that accepts 2-arylacetic acids as substrate is reported in the literature.
α-Hydroxylation of carboxylic acids has only been reported for P450 BSβ and SPα, both of
which are active only on long-chain fatty acids (e.g. myristic acid) and only as peroxygenases.
18 We were therefore interested in whether BM-3 variants could hydroxylate small aromatic
carboxylic acids.
Observations in our laboratory suggested that small charged molecules such as carboxylic acids
are unlikely to be accepted by the hydrophobic active site of BM-3. Recent studies have shown
that protecting groups can strongly influence P450 activity.8, 19 Therefore, using different-
sized ester groups to mask the acid we investigated whether the chain length of the substrate
influences binding and specificity of hydroxylation.
BM-3 shows low activity with moderate enantioselectivity on 2-phenylacetic acid esters (Table
1). For example, the methyl and propyl esters of (S)-mandelic acid were obtained in 90 and
82% enantiomeric excess (ee), respectively. The low total turnover number (TTN; mol product
per mol catalyst) for BM-3 likely reflects an active site evolved for the alkyl tails of fatty acids,
which leads to increased uncoupling (consuming NADPH co-factor without oxidizing the
substrate) for non-natural substrates.
It is known that mutations at F87 can increase BM-3 activity towards small aromatic
compounds.20 We found that the F87A mutation increased the TTN nearly 10-fold and
increased regioselectivity for the α-hydroxylated product to as high as 99% on the propyl ester.
The ee for this reaction depends on the size of the ester group and varies from 43 to 85% ee,
with the highest value for the propyl ester. We also tested variants of BM-3 which were evolved
previously for high activity on medium-chain alkanes, 9-10A and 1-12G (differing by 14 and
16 mutations, respectively, from the wildtype sequence),11 to see if they exhibit higher TTN
on substrates 1a–d. Bioconversions with 1-12G showed 5–20 fold less conversion and very
low regioselectivity for the desired products in comparison to BM-3-F87A and was therefore
excluded from further investigations (data not shown). Variant 9-10A, on the other hand,
showed increased TTN on the propyl and butyl esters. We then constructed 9-10A with the
F87A mutation and found that this 9-10A-F87A variant has the highest TTN (up to 1640) and
gives propyl mandelate in 93% ee. Each 9-10A-F87A enzyme catalyzes the hydroxylation of
254±29 molecules per minute with 25% coupling to cofactor consumption.
9-10A-F87A also hydroxylates substituted substrates such as m-chloro phenylacetic acid
(Table 2). The ee values are comparable to those obtained for phenylacetic acid, although the
highest ee was obtained for the butyl rather than the propyl ester.
The reaction can be improved with a system which regenerates the expensive NADPH cofactor
in situ.21 Use of a regeneration system involving isocitrate dehydrogenase and isocitrate
increased the TTN for the production of propyl mandelate by 9-10A-F87A from 1640 to over
5800 in a 3h reaction with NADPH concentration maintained at 50 μM. Lower concentrations
increased TTN; high concentrations of cofactor inhibit the wildtype enzyme22 and possibly
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our variants. The ee and selectivity were unchanged. Using the regeneration system with 500
nM enzyme yielded 96% conversion of 15 ml of 1 mM propyl phenylacetate in a batch reaction
after 7h.
Motivated by the high enantioselectivity and activity of this variant, we decided to test its ability
to hydroxylate the α-position of the peptide group of buspirone (Buspar®, 4). Buspirone is a
known substrate of human CYP3A4,23 and both it and its human metabolite, 6-
hydroxybuspirone (5), are anti-anxiety agents.24 Bioconversion on 0.5 ml scale with 50 nM
9-10A-F87A gave 3800 TTN and 8.9% conversion of a 2 mM buspirone solution. (R)-6-
hydroxybuspirone (5) was the sole product and was obtained with >99.5% ee. Interestingly,
this R-enantioselectivity is the opposite of that usually observed when buspirone is converted
by natural microbial cultures.24 A 7h bioconversion with cofactor regeneration yielded up to
72% conversion. Thus the bacterial P450 variant efficiently produces an authentic human
metabolite of the drug.
The F87A mutation likely carves out space in the BM-3 active site and allows a wider range
of substrates to be bound with a defined orientation. By varying the chain length of the ester
substrates we can improve catalyst selectivity and probe the active site. Enantioselective
hydroxylation in the α-position of carboxylic acid or peptide derivatives represents a novel
reaction type by P450 BM-3 and opens up a new biocatalytic route to (S)-mandelic acid
derivatives and (R)-6-hydroxybuspirone.
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Table 1
Chiral Product Analysis of P450 Monooxygenase Catalyzed Hydroxylation of the Indicated Phenylacetic Acid Esters
Enzyme Substrate TTN % Selectivitya % ee (S)
BM-3 1a (Me) 105 44 90
1b (Et) 92 29 70
1c (Pr) 63 17 82
1d (Bu) 20 6 71
BM-3-F87A 1a (Me) 25 25 43
1b (Et) 234 86 74
1c(Pr) 623 99 85
1d (Bu) 396 88 75
9-10A 1a (Me) 102 57 77
1b (Et) 63 63 52
1c(Pr) 77 41 85
1d (Bu) 86 25 95
9-10A-F87A 1a (Me) 27 12 39
1b (Et) 115 75 56
1c(Pr) 1640 88 93
1d (Bu) 660 76 89
a
Regioselectivity for mandelic acid esters, side products due to hydroxylation or hydrolysis of ester chain.
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Table 2
Chiral Product Analysis of P450 Monooxygenase Catalyzed Hydroxylation of Chlorinated Phenylacetic Acid Esters
Enzyme Substrate TTN % Selectivitya %ee
9-10A-F87A 3b (Et) 180 70 57
3c (Pr) 940 90 89
3d (Bu) 700 89 94
a
Regioselectivity for mandelic acid ester derivatives
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